Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04103476 · ClinicalTrials.gov registry record · Phase 2
Advancing Postmenopausal Preventive Therapy
A Phase 2 study of Atherosclerosis and Cognitive Decline, sponsored by University of Southern California.
- Active
- Registry status
- Phase 2
- Development phase
- 385
- Enrollment target
- 1
- Study location
NCT04103476 is a Phase 2 study of Atherosclerosis and Cognitive Decline that is active but no longer recruiting, run by University of Southern California. The registered enrollment target is 385 participants, below the 1,060-participant average among 69 other Atherosclerosis trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04103476, a Phase 2 study of Atherosclerosis and Cognitive Decline, is active but no longer recruiting, sponsored by University of Southern California.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 385 participants
- Enrollment target
- 1
- Study location
Study Summary
Advancing Postmenopausal Preventive Therapy (APPT) is a randomized, double-blinded, placebo-controlled trial designed to determine the effects of tissue selective estrogen complex (TSEC) therapy on the progression of subclinical atherosclerosis and cognitive decline in 360 healthy postmenopausal women.
Conditions Studied
Interventions
- OTHER Placebo
- COMBINATION_PRODUCT Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg
Study Locations (1)
California
- University of Southern California Atherosclerosis Research Unit - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 385 participants |
| Start Date | 2021-04-13 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04103476
The ClinicalTrials.gov registry entry for NCT04103476 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 385 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,060-participant average among 69 other Atherosclerosis trials with a reported enrollment target (64% lower). The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Atherosclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04103476 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04103476 about?
NCT04103476 is a clinical study titled "Advancing Postmenopausal Preventive Therapy". Advancing Postmenopausal Preventive Therapy (APPT) is a randomized, double-blinded, placebo-controlled trial designed to determine the effects of tissue selective estrogen complex (TSEC) therapy on the progression of subclinical atherosclerosis and cognitive decline in 360 healthy postmenopausal wom...
What is the current status of trial NCT04103476?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 385 participants. The study started on 2021-04-13. Estimated completion is 2026-12-31.
What conditions does trial NCT04103476 study?
This clinical trial studies the following conditions: Atherosclerosis, Cognitive Decline.
What interventions are being tested in trial NCT04103476?
The interventions under investigation include: Placebo (OTHER), Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04103476?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04103476 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Effects of Angiotensin-Converting Enzyme Inhibitor (Ramipril) Therapy on Blood Vessel Inflammation
COMPLETED · Phase 2
-
Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections
COMPLETED · Phase 2
-
An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks
COMPLETED · Phase 2
-
VEAPS: Vitamin E Atherosclerosis Prevention Study
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.